1-3 of 3
Bryanna L. Norden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2181–2192.
https://doi.org/10.1158/1078-0432.CCR-23-3588
Published: 15 May 2024
View articletitled, The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Open the PDF for The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Ryan B. Corcoran, Khanh T. Do, Jeong E. Kim, James M. Cleary, Aparna R. Parikh, Oladapo O. Yeku, Niya Xiong, Colin D. Weekes, Jennifer Veneris, Leanne G. Ahronian, Gianluca Mauri, Jun Tian, Bryanna L. Norden, Alexa G. Michel, Emily E. Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J. Fetter, Joan S. Brugge, Helen Chen, Naoko Takebe, Richard T. Penson, Dejan Juric, Keith T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, Ursula A. Matulonis, Joyce F. Liu, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1739–1749.
https://doi.org/10.1158/1078-0432.CCR-23-3135
Published: 01 May 2024
View articletitled, Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Open the PDF for Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Qibiao Wu, Haley Ellis, Giulia Siravegna, Alexa G. Michel, Bryanna L. Norden, Ferran Fece de la Cruz, Eranga Roshan Balasooriya, Yuanli Zhen, Vanessa S. Silveira, Jianwe Che, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 198–208.
https://doi.org/10.1158/1078-0432.CCR-23-1317
Published: 05 January 2024
View articletitled, Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Open the PDF for Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma in another window
Includes: Supplementary data